BioMS Medical Corp, a
leading´developer in the treatment of
multiple sclerosis (MS), announced that the University of Alberta has received seventeen additional
patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of
multiple sclerosis (MS).
BioMS Medical, through a subsidiary, licenses these
patents on an exclusive worldwide basis from the University of Alberta.
The additional countries granting patents included Austria,
Belgium, the
Czech Republic,
Denmark,
Finland,
France,
Greece,
Germany,
Ireland,
Luxembourg,
Monaco,
Netherlands,
Spain,
Sweden,
Switzerland,
Ukraine and the
United Kingdom. In total, 50 patents have been granted to the University of Alberta for MBP8298 in 29 countries worldwide, including three patents issued in the United States.
"We continue to build a very powerful intellectual property portfolio for our lead product, MBP8298," said Kevin Giese, President of BioMS Medical.
"With
patent protection in the United States,
Canada and many of the key European countries where MS is highly present, the future commercial value of our MS drug is well protected."